Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.

The tumor-associated-Ag MART-1 is expressed by most human melanomas. The genes encoding an alphabeta TCR from a MART-1-specific, HLA-A2-restricted, human T cell clone have been efficiently transferred and expressed in human PBL. These retrovirally transduced PBL cultures were MART-1 peptide reactive, and most cultures recognized HLA-A2+ melanoma lines. Limiting dilution clones were generated from three bulk transduced PBL cultures to investigate the function of individual clones within the transduced cultures. Twenty-nine of 29 CD8+ clones specifically secreted IFN-gamma in response to T2 cells pulsed with MART-1(27-35) peptide, and 23 of 29 specifically secreted IFN-gamma in response to HLA-A2+ melanoma lines. Additionally, 23 of 29 CD8+ clones lysed T2 cells pulsed with the MART-1(27-35) peptide and 15 of 29 lysed the HLA-A2+ melanoma line 888. CD4+ clones specifically secreted IFN-gamma in response to T2 cells pulsed with the MART-1(27-35) peptide. TCR gene transfer to patient PBL can produce CTL with anti-tumor reactivity in vitro and could potentially offer a treatment for patients with metastatic melanoma. This approach could also be applied to the treatment of other tumors and viral infections. Additionally, TCR gene transfer offers unique opportunities to study the fate of adoptively transferred T cells in vivo.

[1]  S. Rosenberg,et al.  Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. , 1999, Journal of immunotherapy.

[2]  J. Shabanowitz,et al.  The Class I Antigen-processing Pathway for the Membrane Protein Tyrosinase Involves Translation in the Endoplasmic Reticulum and Processing in the Cytosol , 1998, The Journal of experimental medicine.

[3]  F. Brasseur,et al.  A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.

[4]  S. Rosenberg,et al.  Identification of a T-cell receptor from a therapeutic murine T-cell clone. , 1997, Journal of immunotherapy.

[5]  Yutaka Kawakami,et al.  Human tumor antigens recognized by T-cells , 1997, Immunologic research.

[6]  P. Robbins,et al.  Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.

[7]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[8]  F. Marincola,et al.  Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[9]  H. Seigler,et al.  Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. , 1996, Cellular immunology.

[10]  S. Rosenberg,et al.  Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. , 1996, Human gene therapy.

[11]  M. Salgaller,et al.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[12]  F. Brasseur,et al.  A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.

[13]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[14]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[15]  P. Duray,et al.  Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[16]  F. Marincola,et al.  HLA Associations in the Antitumor Response Against Malignant Melanoma , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[17]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[18]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[19]  R. Morgan,et al.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[21]  A Sette,et al.  Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. , 1995, Journal of immunology.

[22]  S. Rosenberg,et al.  Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. , 1995, Cancer research.

[23]  S. Rosenberg,et al.  Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. , 1995, Journal of immunology.

[24]  S. Rosenberg,et al.  Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. , 1995, Blood.

[25]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[26]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[27]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Steinberg,et al.  Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response , 1994, Cancer.

[29]  Who-Wis Nomenclature Sub-Committee on Tcr Desilgnation.  Nomenclature for T cell receptor (TCR) gene segments of the immune system , 1993 .

[30]  D. Morton,et al.  Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. , 1992, Cellular immunology.

[31]  M. Davis,et al.  Low affinity interaction of peptide-MHC complexes with T cell receptors. , 1991, Science.

[32]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[33]  N. Shastri,et al.  Requirement for association of p56 lck with CD4 in antigen-specific signal transduction in T cells , 1991, Cell.

[34]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[35]  P. Parham,et al.  A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2 , 1990, Nature.

[36]  C. Slingluff,et al.  Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. , 1990, Cancer research.

[37]  E. Kawasaki.  18 – SAMPLE PREPARATION FROM BLOOD, CELLS, AND OTHER FLUIDS , 1990 .

[38]  P. Parham,et al.  A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. , 1990, Nature.

[39]  R. Offringa,et al.  Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes , 1989, Cell.

[40]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[41]  J. Parnes.  Molecular biology and function of CD4 and CD8. , 1989, Advances in immunology.

[42]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[43]  S. Rosenberg,et al.  Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma , 1988, The Journal of experimental medicine.

[44]  P. Parham,et al.  Cell-cell adhesion mediated by CD8 and MHC class I molecules , 1988, Nature.

[45]  Michael A. Bookman,et al.  The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56 lck , 1988, Cell.

[46]  C. Rudd,et al.  The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Strominger,et al.  Interaction between CD4 and class II MHC molecules mediates cell adhesion , 1987, Nature.

[48]  R. Zamoyska,et al.  Transfection of the CD8 gene enhances T-cell recognition , 1987, Nature.